Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis

Curr Oncol. 2022 May 19;29(5):3708-3727. doi: 10.3390/curroncol29050297.

Abstract

Neoadjuvant short course radiotherapy (SCRT) followed by consolidation chemotherapy (CCT) is an alternative treatment for locally advanced rectal cancer (LARC). We performed this systematic review and meta-analysis to explore the tumor response and oncological outcomes of this new approach compared to conventional chemoradiotherapy (CRT). An online search of the PubMed, Embase, and Cochrane Library databases was performed. This review included 7507 patients from 14 different cohorts. The pCR rate was higher with SCRT + CCT than that with CRT (RR: 1.60; 95% CI: 1.35−1.91; p < 0.01). SCRT + CCT provided a higher ypN0 response (RR: 1.06; 95% CI: 1.01−1.12; p = 0.02). There were no differences in R0 resection and positive CRM rates; however, more sphincter-preservation surgeries were performed in the SCRT + CCT arm (RR: 1.06; 95% CI: 1.01−1.11; p = 0.02). There was no difference in the OS and DFS between the SCRT + CCT and the CRT arms (OS: HR: 0.85, p = 0.07; DFS: HR: 0.88, p = 0.08). The compliance and toxicity were comparable between the SCRT and CRT groups. In the subgroup analysis, patients who underwent four or more cycles of CCT had better pCR and DFS events. Therefore, SCRT followed by consolidation chemotherapy might be an effective alternative treatment for LARC.

Keywords: consolidation chemotherapy; disease free survival; meta-analysis; overall survival; pathological complete response; rectal cancer; short course radiotherapy.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Chemoradiotherapy
  • Consolidation Chemotherapy
  • Humans
  • Neoadjuvant Therapy
  • Neoplasms, Second Primary*
  • Rectal Neoplasms* / drug therapy
  • Rectal Neoplasms* / surgery

Grants and funding

This research received no external funding.